Mechanisms and modeling of cleavage fracture in simulated heat-affected zone microstructures of a high-strength low alloy steel

International audienceThe effect of the welding cycle on the fracture toughness properties of high-strength low alloy (HSLA) steels is examined by means of thermal simulation of heat-affected zone (HAZ) microstructures. Tensile tests on notched bars and fracture toughness tests at various temperatures are performed together with fracture surface observations and cross-sectional analyses. The influence of martensite-austenite (M-A) constituents and of “crystallographic” bainite packets on cleavage fracture micromechanisms is, thus, evidenced as a function of temperature. Three weakest-link probabilistic models (the “Master-curve” (MC) approach, the Beremin model, and a "double-barrier" (DB) model) are applied to account for the ductileto-brittle transition (DBT) fracture toughness curve. Some analogy, but also differences, are found between the MC approach and the Beremin model. The DB model, having nonfitted, physically based scatter parameters, is applied to the martensite-containing HAZ microstructures and gives promising results

Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

International audienc

Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry

Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score >2 and ≤ 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and 27.5% in those with scores ≤2. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007. © 2020 Hellenic Society of Cardiolog